NCT04999527View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 10, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Healthy Volunteer
Interventions
DRUG

DISC-0974

DISC-0974 is administered (IV infusion or Subcutaneous Injection) as a single dose

DRUG

Placebo

Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

Sponsors

Lead Sponsor

Disc Medicine, Inc
All Listed Sponsors
lead

Disc Medicine, Inc

INDUSTRY

NCT04999527 - Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects | Biotech Hunter | Biotech Hunter